We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
1,2 Vivekanandha Pharmacy College for Women, Sankari, Salem Dt, Tamilnadu, Affiliated to Tn Dr Mgr Medical University, Chennai.
3 Vellalar College Of Pharmacy,Thindal,Erode,Tamilnadu,Affiliated To Tn Dr Mgr Medical University,Chennai
Rabies is one of the most fatal viral infections affecting the central nervous system, with nearly 100% mortality once clinical symptoms appear. The disease is caused by the neurotropic Rabies virus, which is primarily transmitted through bites from infected animals. Current preventive strategies rely on vaccination and post-exposure prophylaxis; however, there is no effective antiviral therapy available after neuronal infection has occurred. A critical step in rabies pathogenesis is the virus's ability to enter peripheral neurons and subsequently travel toward the central nervous system through retrograde axonal transport. Therefore, preventing neuronal entry and blocking neuro invasion represent promising therapeutic strategies. This article reviews the molecular mechanisms involved in rabies virus entry into neurons, the role of viral glycoproteins in host cell interaction, and potential antiviral approaches aimed at preventing neuronal infection and central nervous system invasion. Emerging strategies including receptor blockers, glycoprotein inhibitors, monoclonal antibodies, and innovative drug delivery systems are also discussed. Understanding these mechanisms may contribute to the development of novel therapeutic agents capable of preventing rabies progression after exposure.
Rabies remains a major global public health concern, particularly in developing countries across Asia and Africa. It is an acute viral encephalitis caused by the rabies virus, a member of the genus Lyssavirus within the family Rhabdoviridae. The virus is typically transmitted through the saliva of infected animals during bites or scratches. Once introduced into the body, the virus initially replicates in muscle tissues near the site of infection before entering peripheral nerves and eventually reaching the brain.According to global health reports, rabies causes tens of thousands of human deaths annually, with the majority occurring in rural areas where access to prompt medical treatment may be limited. Although vaccines and immunoglobulin therapy are highly effective when administered promptly after exposure, these treatments become ineffective once the virus has entered the nervous system. Consequently, identifying strategies that prevent viral entry into neurons represents a critical objective in antiviral drug discovery.Recent advances in molecular biology and medicinal chemistry have provided valuable insights into the structure and life cycle of the rabies virus. These insights have revealed several potential therapeutic targets that could be exploited to prevent neuronal infection and inhibit viral spread to the central nervous system.
Structure and Life Cycle of Rabies Virus
The rabies virus is an enveloped, negative-sense single-stranded RNA virus with a bullet-shaped morphology. Its genome encodes five structural proteins that play important roles in viral replication and pathogenesis.
These proteins include:
The infection cycle begins when the virus enters the host through a bite wound. Initially, viral replication occurs in muscle cells near the site of infection. After sufficient viral amplification, the virus attaches to receptors on peripheral nerve endings. Once inside the neuron, the virus travels along microtubules toward the central nervous system via retrograde axonal transport. Eventually, the virus reaches the brain, where extensive replication leads to severe neurological symptoms and fatal encephalitis.
Mechanism of Neuronal Entry
A critical stage in rabies pathogenesis is the entry of the virus into peripheral neurons. This process is primarily mediated by the viral glycoprotein, which facilitates attachment to specific host cell receptors. Several neuronal receptors have been identified as potential entry points for the virus, including the nicotinic acetylcholine receptor, neural cell adhesion molecule (NCAM), and the p75 neurotrophin receptor.Following receptor binding, the virus enters the host cell through receptor-mediated endocytosis. Acidification within the endosomal compartment triggers conformational changes in the viral glycoprotein, allowing membrane fusion and release of the viral ribonucleoprotein complex into the cytoplasm.Preventing this early interaction between the viral glycoprotein and host receptors represents a promising strategy for blocking rabies infection before the virus gains access to the nervous system.
Strategies to Prevent Neuronal Entry
Glycoprotein Inhibitors
Because the viral glycoprotein plays a crucial role in host cell attachment and membrane fusion, it represents an attractive target for antiviral drug development. Small molecules capable of binding to the receptor-binding domain of the glycoprotein could theoretically block viral attachment and prevent infection.Structure-based drug design and molecular docking approaches may assist in identifying compounds that interfere with glycoprotein-receptor interactions.
Neutralizing Monoclonal Antibodies
Neutralizing monoclonal antibodies directed against the viral glycoprotein have shown promise in experimental studies. These antibodies bind to specific epitopes on the glycoprotein surface and prevent the virus from attaching to host receptors.Such antibodies could potentially serve as alternatives to traditional rabies immunoglobulin therapy in post-exposure treatment.
Host Receptor Blockers
Another possible strategy involves blocking host receptors that facilitate viral entry. Molecules capable of competitively inhibiting receptor binding sites may prevent the virus from attaching to neuronal membranes.However, this approach must be carefully designed to avoid interference with normal physiological functions of neuronal receptors.
Fusion Inhibitors
Fusion inhibitors aim to prevent the merging of viral and cellular membranes during endocytosis. By stabilizing the viral glycoprotein in its pre-fusion state, these compounds may block the release of viral genetic material into the host cell cytoplasm.Fusion inhibitors have been successfully used in the treatment of other viral infections, suggesting their potential application in rabies therapy.
Blocking Axonal Transport of Rabies Virus
After entering neurons, the rabies virus travels toward the central nervous system through retrograde axonal transport. This movement is mediated by motor proteins such as dynein that transport viral particles along microtubules.Targeting the interaction between viral proteins and cellular motor proteins could potentially disrupt viral transport and delay or prevent the spread of infection to the brain. Although this strategy remains largely theoretical, it represents an interesting area for future investigation.
Overcoming the Blood–Brain Barrier
The blood–brain barrier represents a major obstacle for antiviral drug delivery to the central nervous system. This barrier is composed of tightly connected endothelial cells that prevent most molecules from entering brain tissue.Several approaches have been proposed to enhance drug delivery across the blood–brain barrier, including:
These technologies may enable therapeutic agents to reach infected neurons within the brain.
FUTURE PERSPECTIVES
Recent advancements in medicinal chemistry, computational modeling, and biotechnology have opened new avenues for antiviral drug discovery. Structure-based drug design, molecular docking studies, and artificial intelligence-assisted screening methods may accelerate the identification of compounds capable of inhibiting rabies virus entry and replication.Combination therapy strategies targeting multiple stages of the viral life cycle may also improve treatment outcomes. Continued interdisciplinary research integrating virology, pharmacology, and medicinal chemistry will be essential for developing effective therapeutics against rabies.
CONCLUSION
Rabies remains one of the most lethal viral infections affecting humans. The ability of the rabies virus to invade peripheral neurons and spread to the central nervous system presents a major challenge for therapeutic intervention. Preventing neuronal entry and blocking axonal transport represent promising strategies for antiviral drug development. Targeting viral glycoproteins, host cell receptors, and intracellular transport mechanisms may provide new opportunities for designing effective anti-rabies agents. Further research focusing on these molecular targets may ultimately lead to novel therapeutic approaches capable of preventing rabies progression after exposure.
REFERENCES
Mounika K., Dr. R. Thirumurthy, S. Annalakshmi, Strategies to Prevent Neuronal Entry and Central Nervous System Invasion of the Rabies Virus: Emerging Targets for Antiviral Drug Development, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 4, 2013-2018, https://doi.org/10.5281/zenodo.19551712
10.5281/zenodo.19551712